Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland

Abiraterone acetate (ABI) and Enzalutamide (ENZA) are second-generation hormone drugs that show breakthrough activity in post-chemotherapy, metastatic castration-resistant prostate cancer (mCRPC). The leading oncological and urological guidelines indicate both drugs with the same strong recommendati...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-04, Vol.13, p.1108937-1108937
Main Authors: Sigorski, Dawid, Wilk, Michał, Gawlik-Urban, Angelika, Sałek-Zań, Agata, Kiszka, Joanna, Malik, Mateusz, Czerko, Katarzyna, Kuć, Kamil, Szczylik, Cezary, Kubiatowski, Tomasz, Cybulska-Stopa, Bożena, Filipczyk-Cisarż, Emilia, Bodnar, Lubomir, Skoneczna, Iwona
Format: Article
Language:English
Subjects:
abiraterone acetate
enzalutamide
metastatic prostate cancer
Oncology
real-word study
targeted therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abiraterone acetate (ABI) and Enzalutamide (ENZA) are second-generation hormone drugs that show breakthrough activity in post-chemotherapy, metastatic castration-resistant prostate cancer (mCRPC). The leading oncological and urological guidelines indicate both drugs with the same strong recommendation. There is a lack of randomized trials which compare the efficacy of ABI and ENZA. The current study aimed to compare the effectiveness of the drugs with an analysis of prognostic factors related to those drugs. The study included 420 patients with docetaxel (DXL) pretreated mCRPC from seven Polish cancer centers. Patients were treated according to inclusion and exclusion criteria in the Polish national drug program (1000 mg ABI and 10 mg prednisone, =76.2%; ENZA, 160 mg; =23.8%). The study retrospectively analyzed the overall survival (OS), time to treatment failure (TTF), PSA 50% decline rate (PSA 50%) and selected clinic-pathological data. In the study group, the median OS was 17 months (95% CI: 15.6-18.3). The median OS (26.1 vs. 15.7 mo.;
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1108937